Abstract:Abstract Background The introduction of anti-PD-1 antibody has greatly improved the clinical outcomes of patients with non-small cell lung cancer(NSCLC). Here we retrospectively analyzed the efficacy of PD-1 antibody-based therapy in patients with locally advanced un-operable or metastatic NSCLC patients and report an association between peripheral blood biomarkers with clinical response in these patients. Methods We conducted a single-center study by including medical record data for NSCLC patients treated with PD-1 antibody first-line or posterior-line either as monotherapy or in combination with chemotherapy. The patients enrolled from 2020 to 2022. Dynamic evaluation of multiple Th1 and Th2 cytokines in the blood serum, as well as analysis of the phenotype of T cells from peripheral blood, was conducted to explore the correlation between cytokines levels, T cell phenotype, and clinical response. Results 88 stage IIIA-IV NSCLC patients were enrolled. 60(68.18%) patients achieved partial response(PR), 13 (14.77%) patients were stable(SD) and 15(17.05%) patients had progressed disease (PD). The disease control rate (DCR) was 82.95%. Our results suggested a significant reduction (P = 0.002, P < 0.005) of lymphocyte absolute counts after treatment in the patients with disease progression(PD). Higher levels of IFN-γ(P = 0.023,P < 0.05), TNF-α(P = 0.00098,P < 0.005 ), IL-4 (P = 0.0031 ,P < .0.005), IL-5 (P = 0.0015,P < 0.005) and IL-10 ( P = 0.036 ,P < 0.05) were detected in peripheral blood prior to the treatment in PR group comparing with PD group.. Besides, those patients with high IL-5、IL-13、IL-4、IL-6、IFN-γ and TNF-α(> 10ng/ml) had superior PFS than those with low IL-5、IL-13、 IL-4、IL-6、IFN-γ and TNF-α(< 10ng/ml). Moreover, the expression of PD-1 expression on CD8 + Tcells was positive associated with the clinical response between response patients (PR)and non-response(SD + PD)patients(P = 0.042, P < 0.05). Conclusions The findings of this study imply that the decrease in absolute blood lymphocyte counts after treatment is correlated to the progression of the disease. It is possible that serum cytokine concentrations can forecast the effectiveness and survival rate of anti-PD-1 blockade therapy in NSCLC patients. In addition, the expression of PD-1 expression on CD8 + Tcells was positive associated with the better clinical response as well. The findings of our study indicated the potential of peripheral blood biomarkers analysis to offer predictive value of PD-1-targeted treatments to NSCLC patients. Large prospective studies need to further clarify the value of these biomarkers.

Increased death and exhaustion of CD69 high T cells and NK cells are associated with PD-1 antibody application in the in vitro co-culture system

Increased Death and Exhaustion of CD69high T Cells and NK Cells Are Associated with PD-1 Antibody Application in the in Vitro Co-Culture System

The Combination of Anti-Kir Monoclonal Antibodies with Anti-Pd-1/pd-l1 Monoclonal Antibodies Could Be a Critical Breakthrough in Overcoming Tumor Immune Escape in NSCLC

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Correlation of PD-1 Expression on Peripheral Blood T Cells in Non-Small Cell Lung Cancer and the Efficacy of Immunotherapy

CD161+CD127+CD8+ T Cell Subsets Can Predict the Efficacy of Anti-Pd-1 Immunotherapy in Non-Small Cell Lung Cancer with Diabetes Mellitus

[Expression of PD-1 and PD-L1 in the Peripheral Blood of Advanced Non-Small-cell Lung Cancer Patients and Its Implications].

PD-1(+) IFN-gamma(+) subset of CD8(+) T cell in circulation predicts response to anti-PD-1 therapy in NSCLC

Peripheral CD4 + T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer

Proliferation of Pd-1+Cd8 T Cells in Peripheral Blood after Pd-1-Targeted Therapy in Lung Cancer Patients

Early‐like Differentiation Status of Systemic PD‐1+CD8+ T Cells Predicts PD‐1 Blockade Outcome in Non‐small Cell Lung Cancer

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients

T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer

Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer

Single-cell RNA Sequencing Reveals Cellular and Molecular Immune Profile in a Pembrolizumab-responsive PD-L1-negative Lung Cancer Patient

Role of CXCR3 Signaling in Response to Anti-Pd-1 Therapy.

Autologous cytokine‐induced killer ( CIK ) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study

PD-1-positive Natural Killer Cells Have a Weaker Antitumor Function Than That of PD-1-negative Natural Killer Cells in Lung Cancer

[Expression of PD-1/PD-L1 in Peripheral Blood Mononuclear Cells in Lung Cancer Patients and Its Biological Significance].

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion